Zevra Therapeutics (NASDAQ:ZVRA) PT Raised to $21.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price target raised by stock analysts at Roth Mkm from $19.00 to $21.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Roth Mkm’s target price suggests a potential upside of 177.04% from the stock’s current price.

Other analysts have also issued research reports about the stock. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday, September 18th. HC Wainwright lifted their price objective on Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Finally, JMP Securities began coverage on Zevra Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $17.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $7.58 on Tuesday. The business has a 50 day simple moving average of $7.07 and a 200 day simple moving average of $5.72. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.95. The company has a market capitalization of $317.25 million, a PE ratio of -5.61 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter in the prior year, the firm posted ($0.15) EPS. On average, sell-side analysts forecast that Zevra Therapeutics will post -1.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction dated Tuesday, July 16th. The stock was bought at an average cost of $6.81 per share, with a total value of $68,100.00. Following the purchase, the director now owns 20,000 shares of the company’s stock, valued at $136,200. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have bought 22,000 shares of company stock valued at $140,340. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new stake in Zevra Therapeutics during the 1st quarter worth about $64,000. The Manufacturers Life Insurance Company boosted its stake in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. Focus Financial Network Inc. ADV acquired a new stake in shares of Zevra Therapeutics during the 4th quarter worth approximately $141,000. Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics during the 4th quarter worth approximately $177,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after buying an additional 17,557 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.